Indeed, despite the clear effectiveness of CDK4/6i demonstrated in clinical trials with an almost doubling progression free survival (8–10), resistance is poised to become a major challenge for the management of advanced ER+ breast cancer in the developed world as it is expected that all patients in this setting will receive CDK4/6i as part of their treatment. Here, CDK4 is linked to breast carcinoma.